Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Urologix's Days Sales Outstanding for the
three
months ended in Mar. 2015 was 47.
Urologix's Days Inventory for the
three
months ended in Mar. 2015 was 81.17.
Urologix's Days Payable for the
three
months ended in Mar. 2015 was 50.45.
Therefore, Urologix's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2015 was 77.72.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Urologix Cash Conversion Cycle Related Terms
Urologix Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Urologix's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ULGX vs MFST, GTHP, ESMC: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Urologix's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Urologix Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Urologix's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Urologix's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Urologix's Cash Conversion Cycle for the fiscal year that ended in Jun. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Urologix (ULGX) has a Cash Conversion Cycle of 77.72 as of Mar. 2015. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Urologix and its competitors.
Is Urologix's Cash Conversion Cycle too high?
Urologix's current Cash Conversion Cycle is 77.72. The Medical Devices & Instruments industry median Cash Conversion Cycle is 158.08. Urologix's value of 77.72 is 50.8% below this industry median.
How does Urologix's Cash Conversion Cycle compare to MFST and GTHP?
Urologix's Cash Conversion Cycle of 77.72 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 158.08. Urologix's value of 77.72 is 50.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 158.08, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Urologix's current Cash Conversion Cycle of 77.72 is 50.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Urologix and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 158.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Urologix's current Cash Conversion Cycle is 77.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Urologix stock overvalued right now?
Urologix (ULGX) has a current Cash Conversion Cycle of 77.72. The current Cash Conversion Cycle is 77.72 and 50.8% below the Medical Devices & Instruments industry median of 158.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Urologix (ULGX), the current Cash Conversion Cycle is 77.72 as of Mar. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ULGX has been successfully added to your 
